Company: Frederick National Laboratory for Cancer Research
Job title: Director, Protein Expression Laboratory, NCI RAS Initiative
Dr. Esposito is currently the Director of the Protein Expression Laboratory (PEL) at the Frederick National Laboratory for Cancer Research. The PEL is currently focused on providing production of Ras and Ras-related proteins for the National Cancer Institute’s RAS Initiative. These proteins are used for a wide-ranging attack on Ras biology including structural biology, biochemistry, and biophysics. They also serve as the fundamental basis for the development of screens and assays to support our internal drug discovery efforts. In addition, the PEL still assists in the generation of proteins of interest to investigators in the intramural program of the NCI and invents and develops new technologies for protein expression and production. Dr. Esposito received his B.A. in Chemistry at La Salle University in Philadelphia, and his Ph.D. in Biochemistry at the Johns Hopkins University Bloomberg School. Dr. Esposito previously worked for Life Technologies, where he helped to develop the Gateway recombinational cloning system.
Targeting KRAS Directly with Novel Drug Discovery Efforts at the NCI RAS Initiative 8:30 am
• The NCI RAS Initiative is developing new approaches for direct targeting of KRAS • New technologies and assays from the RAS Initiative can enable other drug discovery efforts on RAS • Collaborative efforts between industry, academic, and the RAS Initiative have had significant impacts on improving our understanding of the biochemistry and biophysics of…Read more
day: Day One